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SumlTlary 
The priming of an immune response against a major histocompatibility complex class I-restricted 
antigen expressed by nonhematopoietic cells involves the transfer of that antigen to a host bone 
marrow-derived antigen presenting cell (APC) for presentation to CD8 + T  lymphocytes. Den- 
dritic cells  (DC), as bone marrow-derived APC, are first candidates for presentation of tumor- 
associated antigens  (TAA). The aim of this study was to see whether DC are able to prime in 
vivo antigen-specific  cytotoxic T  lymphocytes after exposure  to  a soluble  protein  antigen  in 
vitro.  Lacking  a  well-defined  murine  TAA,  we  took  advantage  of 13-galactosidase  (13-gal)- 
transduced tumor cell lines as a model in which [3-gal operationally functions as TAA. For in 
vivo priming both a DC line,  transduced or not transduced with the gene coding for murine 
GM-CSF, and fresh bone marrow-derived DC  (bm-DC), loaded in vitro with soluble ~-gal, 
were used. Priming with either granulocyte macrophage colony-stimulating factor-transduced 
DC  line  or fresh  bm-DC  but  not  with  untransduced  DC  line  generated  CTL  able  to  lyse 
13-gal-transfected target cells.  Furthermore,  GM-CSF was necessary for the DC line to effi- 
ciently present  soluble  [3-gal as  an  H-2Ld-restricted  peptide  to  a  [3-gal--specific CTL  clone. 
Data  also  show  that  a  long-lasting immunity  against  tumor  challenge  can be  induced using 
[3-gal-pulsed bm-DC as vaccine. These results indicate that effector cells can be recruited and 
activated  in  vivo  by  antigen-pulsed  DC,  providing  an  efficient  immune  reaction  against 
tumors. 
T 
he  cloning  of genes  encoding tumor-associated  anti- 
gens (TAA) recognized by T  cells in both humans and 
rodents  (1,  2)  have  reopened  the  never-ending  hope  of 
curing  cancer  through  immunological  interventions.  Ac- 
tive  immunization with such antigens  is  expected  to acti- 
vate tumor-specific CTL,  a process requiring T  cell prim- 
ing  in  the  context  of MHC  class  I  pathway  (3).  CTL 
induction  usually  follows  antigen  processing  via  endoge- 
nous pathway, although exceptions have been reported  (4, 
5).  Host  bone  marrow-derived  APC  induced  in  vivo  a 
CTL-mediated protective immunity against an MHC  class 
I-negative tumor by uptaking and processing for presenta- 
tion within their own MHC-I  (6).  Among bone marrow- 
derived APC,  dendritic  cells  (DC)  are  the  most attractive 
candidates for this purpose since several studies suggest that 
they  are  particularly  effective  in  stimulating  both  CD4 + 
A preliminary account of this work was presented to the Keystone Sym- 
posia Conference on Dendritic Cells: Antigen-presenting Cells of T and 
B Lymphocytes,  in Taos, NM, 10-16 March 1995. 
and CD8 § naive T  lymphocytes (7-12). In fact DC express 
the costimulatory molecules B7.1  and B7.2, adhesion mol- 
ecules, and may release soluble factors, all needed for an ef- 
ficient  triggering  of the  immune  response  (13).  Further- 
more, DC were shown to be necessary to generate T  cell- 
mediated tumor-specific immunity in some murine models 
(14-16).  This  response  was  dominated  by  CD4 +  T  cells 
and was generally unable to completely inhibit tumor take 
unless,  as in the case of BCL1 lymphoma, an antiidiotypic 
antibody response can be generated (16). This limited effect 
on  tumors  could be  due  to  the  incomplete  activation  of 
CD8 §  T  cells,  and particularly of CTL, which are consid- 
ered  as  the  main  effectors  able  to  destroy  tumor  cells  in 
vivo (3).  DC, exposed to soluble antigen in vitro,  are able 
to  sensitize  antigen-specific  T  lymphocytes in vivo,  in  an 
MHC-II-restricted  fashion  (7).  Since  CTLs  appear  to  be 
necessary to induce tumor rejection in several animal mod- 
els,  we  addressed  the  question  of whether  DC  pulsed  in 
vitro with  a soluble  antigen were able  to induce  cytolytic 
MHC-I-restricted CD8 + T  cells as well as a protective an- 
titumor immunity in vivo. 
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Animals.  Female BALB/c (H-2 a) of 8 and 12 wk of age were 
purchased  from  Charles  River Laboratories  (Calco,  Italy).  This 
study was approved by the Institutional Ethic Committee for the 
use of animals in experimental research. 
Cell Lines.  D2SC/1  (H-2 d) is a DC line obtained by retrovi- 
ral  immortalization  of BALB/c  spleen-derived  DC,  through  a 
previously described procedure  (17),  and generously provided by 
Dr. P. Ricciardi-Castagnoli (Consiglio Nazionale delle Ricerche, 
Milano,  Italy).  D2SC/I-GM  was  obtained  by  transduction  of 
D2SC/1 cell line with the retroviral vector LmGMSN. GM-CSF 
cDNA was  obtained  from  a  murine  CTL  line by reverse tran- 
scription PCR using GM-CSF-specific primer ends modified to 
include EcoRI and  BamHI sites  at  5'  and  3',  respectively.  The 
resulting  517-bp  GM-CSF  insert  was  ligated  into  EcoRI  and 
BamHI  of  the  LXSN  retroviral  vector  (18),  to  obtain  the 
LmGMSN  vector.  Retroviral  particles  were  obtained  by  trans- 
infection  technique,  as  described  (19,  20).  D2SC/1-GM  cells 
released  "-'40 ng/ml per  106  cells  of GM-CSF  as  measured  by 
capture  ELISA.  The  clone F1.A11  (H-2  d)  expressing  [3-gal  was 
obtained by transduction  of spontaneously transformed  BALB/c 
fibroblast cell line I=1  (Colombo, M.P.,  unpublished results)  with 
the LBSN retroviral vector (19).  P13.1  (H-2d),  a P815  mastocy- 
toma  line  derivative  expressing  [3-gal  (5),  and  the  CTL  clone 
0805.B,  (21)  recognizing the  13-gal naturally  processed,  H-2L  d- 
restricted,  epitope p876-884  (22)  were kindly provided by Pro- 
fessor  H.  G.  1Kammensee  (Deutsches  Krebsforschungzentrmn, 
Heidelberg, Gemaany).  P815  (H-2  a) and EL4 (H-2 b) tumor lines 
were used as negative control targets in SICr release assay. All cells 
were  maintained  in  RPMI  1640  supplemented  with  10%  FCS 
except  for  DC  lines,  which  were  grown  in  5%  1=CS-supple- 
mented IMDM.  The synthetic peptide  ~GP1  ([3-gal,  p876-884, 
TPHPARIGL)  was  a  generous  gift of Dr.  N.  1Kestifo  (National 
Cancer Institute, Bethesda, MD). 
Bone Marrow DC Preparation.  Fresh  DC  were  obtained  from 
mouse  bone  marrow  precursors  as  previously  described  (23). 
Bone marrow-derived  (bm)  DC  were used for in vivo priming 
after 9-11  d of in vitro maturation driven by recombinant mouse 
GM-CSF at 500 U/ml. The percentage of mature DC was deter- 
mined by cell surface and intracellular antigens staining and ML1K 
assay as previously described (17).  Preparations  always resulted in 
>90% potent MLR stimulator DC (not shown). 
Immunization and CTLAssay.  Before  injection  in  vivo,  DC 
lines as well as fresh bm-DC were exposed in vitro to 100 b~g/ml 
13-gal grade X  (Sigma Chemical Co., Milano,  Italy)  for 18-20 h 
to allow protein processing. 2-5  ￿  106 D2SC/1 and D2SC/1-GM 
cells or 5  ￿  10  s fresh DC were injected intraperitoneally in 200 
~1 PBS after extensive washing in FCS-ffee medium. After 10-12 d, 
spleens  were  removed  from  three  to  four  immunized  mice, 
pooled, and a single cell suspension prepared by mechanical disso- 
ciation.  Splenocytes were restimulated at 5  ￿  10  (' cells/ml with 
the synthetic  peptide  [3GP1  (1  ~M)  or 5  ￿  105  irradiated  (150 
Gy)  F1.All  cells/ml in  the  presence  of 20  U/ml recombinant 
human  IL-2 (EUROCETUS, Milano, Italy). After 5-7 d,  viable 
cells were harvested and tested in a SlCr release assay (24) for their 
ability to lyse the 13-gal-expressing tumor cell line P13.1. 
Flow Cytometry.  The CD4/CD8 profile of in vivo primed T 
lymphocytes were analyzed by flow cytometry after conventional 
mAb staining (17).  The following mAbs were used: FITC-conju- 
gated anti-CD4,  clone 1KM4-5,  and  anti-Thyl.2,  clone 53-2.1, 
and  PE-conjugated  anti-CD8,  clone  53-6.7  (Pharmingen,  San 
Diego,  CA).  Analysis was  performed  on  a  FACScan  |  (Becton- 
Dickinson,  Milano,  Italy);  data were collected on  5,000-10,000 
viable cells and  analyzed using Lysis  1I  |  software.  To detect cell 
surface expression of leukocyte markers on DC cell lines, immu- 
nostaining was performed as previously described  (17)  using the 
following mAbs: M1/42,  anti-MHC-I; B21.2,  anti-MHC-II  (I- 
Ab'd); 2D2C,  anti-CD44;  M1/69,  anti-heat-stable  antigen;  3E2, 
anti-ICAM-1;  1G10,  anti-B7-1;  GLI,  anti-B7-2;  and  unrelated 
isoWpe-matched mAbs as controls. 
In  Vivo Protection Studies.  Mice  were  immunized  following 
the schedule of Table 1, and control naive animals received in the 
left  rear  flank  a  subcutaneous  challenge  of F1.All  living cells 
(104) 10-12 d after vaccination. Mice given the tumor subcutane- 
ously were  inspected  for tumor  growth  and  size twice  a  week. 
The  differences in tumor  take  between  control and  imnmnized 
mice were statistically evaluated by chi-square test, considering a 
X  2 value  >3.8  as  indicative  of significant  difference  at  <0.05 
level. 
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Figure 1.  (A) Secondary response in mice that have been primed with 
the antigen-pulsed  DC lines. CD4 + T lymphocytes,  purified from spleen 
of naive or from mice immunized with DC lines pulsed in vitro with sol- 
uble [B-gal or with irradiated F1.A11 tumor cells, were cultured at the in- 
dicated cell numbers in presence of [3-gal (10 btg/ml) and syngeneic irra- 
diated spleen APC. After 72 h the cultures were pulsed overnight with 1 
DCi/well [3H]TdP, and harvested on glass fiber filters 18 h later. Incorpo- 
rated radioactivity was measured by liquid scintillation counting.  CD4 + T 
cells were immunoselected  from total  spleen cells population  by nylon 
wool purification  followed  by complement-mediated lysis of CD8 + T 
cells in presence of the rat anti-mouse mAb 53-6.7  (TIB105), resulting in 
>85% pure CD4 + T cells as confirmed  by immunostaining  and flow cy- 
tometry  (not  shown).  (B)  Recognition  of  MHC-I-restricted  ]3-gal 
epitope by lymphocytes primed in vivo with DC lines. After immuniza- 
tion with the indicated  vaccine  (top), lymphocytes  were restimulated  in 
vitro (5 d) in the presence oCIBGP1 peptide (l I.~M); at the end of the cul- 
ture lymphocytes were tested in a SlCr-release assay using P815 (A) and 
P13.1 (11) as targets. 
318  Soluble Antigen-loaded Dendritic Cells Prime CTL against  Tumor Antigen Table  1.  Schedule  for In  Vivo Priming Using bm-DC Pulsed In 
~'tro with Soluble fl-gal 
Day 0  Day 5 
Vaccine  Boost 
Group*  (dose/mouse)  (dose/mouse) 
1  bm-DC (5 ￿  t05 cells) 
2  bm-DC (5 X  105 cells)  [3-gal (50 ~g) 
3  bm-DC +  [3-gal* (5 ￿  10  s cells)  -- 
4  bm-DC +  [3-galr (5 ￿  105 cells)  [3-gal (50 b~g) 
5  ~-gal (50 I~g) 
6  [3-gal (50 ~g)  [3-gal (50 b~g) 
7  [3-gal (50 b~g) in CFA (1:t)  -- 
8  [3-gal (50 b~g) in C. parvum 
(100 ~g) 
0  -- 
*Vaccines and  soluble protein  boost were  administered intraperito- 
neally. All groups received a challenge of  live F1.A11 (10  4 cells/mouse; 
subcutaneously) on day 12 after immunization. 
*Before injection, bm-DC were pulsed in vitro with 100 bLg/ml [3-gal, 
for 18-20 h. 
Results 
The  DC  Line  D2SC/1  Exposed  to  Soluble  fl-gal  In  Vitro 
Primes an Antigen-specific  Cytolytic T  Cell Response after a Sin- 
gle Immunization  In  Vivo.  To  assess  the  ability  of DC  to 
prime  a  CTL  response  against  a  soluble  protein  in  vivo, 
mice were injected intraperitoneally with 2-5  ￿  106 D2SC/ 
1 or D2SC/1-GM cells previously exposed in vitro to solu- 
ble  ]3-gal.  10-12  d  after  immunization,  mice  were  killed 
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and  their  spleen  cells  harvested  and  placed  in  secondary 
culture in vitro. As expected,  a CD4-mediated  [3-gal-spe- 
cific proliferative response was elicited (Fig.  1 A). To assess 
cytolytic activity,  splenocytes  from vaccinated  mice  were 
placed in a secondary in vitro  culture with the  [3-gal syn- 
thetic peptide  [3GP1, or ~-gal gene-transduced tumor cells 
(not  shown),  and  tested,  5  d  later,  for  lytic  activity  on 
13-gal-transfected P13.1  and parental P815 cells  (Fig.  1 B). 
Splenocytes from mice primed in vivo with D2SC/1  cells 
+  [3-gal  were  unable  to  specifically  lyse  P13.1  whereas 
splenocytes from mice primed with D2SC/1-GM  +  [3-gal 
lysed P13.1 but not P815. Thus only the priming with the 
GM-CSF-transduced cell line elicited antigen-specific CTL. 
Vaccination with DC lines not pulsed with the soluble pro- 
tein did not induce [3-gal-specific CTL, while  a prolifera- 
tive response against FCS components could not be avoided. 
GM-CSF Allows the In  Vitro MHC-I-restricted Presentation 
of Soluble Antigen by D2SC/1  Cell Line.  Further  investiga- 
tion of the effect of GM-CSF transduction on the DC line 
D2SC/1  did not reveal modifications in the pattern  of cell 
surface  markers  but,  as  "already  observed  after  addition  of 
recombinant mouse GM-CSF to another immortalized cell 
line (17), GM-CSF-transduced DC became free in suspen- 
sion  and  acquired  a  more  dendritic  morphology  (not 
shown). 
Moreover, that GM-CSF modifies the ability of D2SC/1 
to  present  [3-gal  was  clearly  shown  by  experiments  in 
which  D2SC/1  and  D2SC/1-GM  pulsed  with  either 
[3GP1  peptide  or soluble  [3-gal were used as targets  of the 
[3-gal-specific,  CTL  clone  0805.B.  In  fact,  while  both 
D2SC/1  and D2SC/1-GM  were  lysed if pulsed  with  the 
peptide  [3GP1  (Fig.  2 A), only D2SC/1-GM was lysed af- 
ter pulsing with soluble [3-gal (Fig. 2  B). This result clearly 
indicates that the peptide was correctly displayed within the 
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Figure  2.  Recognition  of ]3-gal naturally processed 
epitope by [3-gal-specific  0805.B CTL clone. (A) Recog- 
nition of [3GPl-pulsed targets; (B) recognition of soluble 
]3-gal-pulsed targets. Lytic activity  was assayed in a 51Cr re- 
lease after incubation of  target cells with soluble 13-gal (100 
btg/rnl, 18-20 h) or ]3GP1 peptide (1-0.001 IxM; 2 h). 
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Figure 3.  Recognition ofMHC-l-restricted [3-gal  epitope by lympho- 
cytes primed in vivo with bm-DC. After immunization with the indi- 
cated vaccine, lymphocytes were restimulated in vitro (5 d) in the pres- 
ence of ~GP1 peptide. At the end of the culture live lymphocytes were 
tested in a 51Cr release assay  using P815 (A) and P13.1 (m) as targets. (a) 
bm-DC  pulsed with  [3-gal; (b)  bm-DC  pulsed with  [3-gal plus [3-gal 
boost; (c) [3-gal; (d) [3-gal  plus [3-gal  boost. 
MHC-I  of both  DC  lines  but  that  only DC  transduced 
with GM-CSF can process the soluble protein for MHC-I 
presentation. 
Fresh bm-DC Process Soluble fl-gal In  Vitro and Prime Anti- 
gen-specific CTL In  Vivo.  To  investigate  whether  the  in 
vivo priming of CTL is a property restricted to immortal- 
ized DC  lines,  experiments were  run  in parallel by using 
bm-DC.  Fresh  DC  were  exposed  to  soluble  antigen  in 
vitro with the same procedure and concentration used for 
D2SC/1  cells  and  injected  intraperitoneally  in  BALB/c 
mice (Table 1). 500,000 bm-DC, pulsed in vitro with solu- 
ble ~-gal, were sufficient to prime antigen specific CTL in 
vivo, whereas no  evidence of CTL  activation was seen in 
mice immunized once or twice with soluble [3-gal or with 
unloaded bm-DC  (Fig. 3). 
Lymphocytes primed in vivo with DC and expanded by 
secondary in vitro cultures, were  enriched in T  cells. Par- 
ticularly, we found that CD8 + cells were 55-70% and  15- 
35% in DC versus tumor cell-primed lymphocytes, respec- 
tively. Furthermore,  lymphocytes from mice primed with 
DC  showed a blastlike morphology, indicating a probable 
entry in  G1  phase,  since  their forward scatter/side scatter 
parameters were 500:250 while parameters of lymphocytes 
from mice primed with tumor cells were 200 : 50, the latter 
without a significant difference from naive lymphocyte size 
(Table 2). 
Vaccination with DC Pulsed with fl-gal Protects Mice Against a 
Challenge with fl-gal-transduced  Tumor Cells.  To test whether 
the immune response induced by bm-DC can induce resis- 
tance against a challenge with live tumor cells, 10-12 d  af- 
ter immunization mice were injected subcutaneously with 
104 viable F1.A11 cells. Immunization with bm-DC pulsed 
with soluble [3-gal protected 60% of challenged mice while 
mice receiving also a soluble [3-gal boost 5 d after the prim- 
ing with pulsed bm-DC were completely protected against 
tumor challenge. Mice immunized with [3-gal, boosted or 
not with the soluble protein, did not show statistically sig- 
nificant difference in tumor take as compared to naive mice 
which received the same  challenging dose. No protection 
was  seen  also  in  mice  receiving  unloaded  bm-DC  ac- 
companied or not by a boost of soluble protein (Fig. 4 A). 
Vaccination  with  soluble  [3-gal  admixed  with  CFA  or 
Corynebacterium  parvum  adjuvants  did  not  result  in  tumor 
protection (Fig. 4 B). 
Discussion 
To  directly investigate  the  in vivo priming  of a  CD8- 
mediated  T  cell  response  after  prophylactic  vaccination 
with  soluble protein loaded DC,  we  took advantage  of a 
previously described immortalized DC  line  (17)  to  set up 
the  model,  and  from  the  complete set of reagents that  an 
antigen like [3-gal may offer. In fact, [3-gal-soluble protein, 
its immunogenic peptide as well as a retroviral vector able 
to transduce the gene into tumor cells, were all available. In 
addition, [3-gal has been chosen because, as soluble protein, 
Table 2.  Activation of In  Vivo Primed Lymphocytes after In  Vitro Secondary Culture with fl-gal-derived Synthetic Peptide 
Vaccine  Mean forward scatter  Percent CD4  Percent CD8  CD4/CD8 
bm-DC  200  24  11  2.18 
bm-DC +  [3-gal boost  200  32  9  3.5 
bm-DC +  [3-gal*  500  6  70  0.08 
bm-DC +  [3-gal +  [3-gal boost  400  20  60  0.33 
[3-gal  200  65  22  3.03 
[3-gal +  [3-gal boost  200  70  24  2.93 
F1.All  200  48  38  1.26 
Lymphocytes were restimulated in presence of [3GP1 (1 btM) for 5 d in vitro. 
*Before injection, bm-DC were pulsed in vitro with 100 p~g/ml [3-gal  for 18-20 h. 
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it lacks intrinsic  properties that allow its  entry into the cell 
outside the  endosomal compartment and because it is un- 
able to stimulate CTL in vivo (5). 
We observed that DC lines loaded in vitro with soluble 
antigen were able to activate antigen-specific CTL if trans- 
duced with GM-CSF gene. This confirms previous obser- 
vations  which  indicate  GM-CSF  as  a  "pro-presentation" 
cytokine (25). In fact, GM-CSF is able to enhance the im- 
mune  response  initiated  by  DC,  including  immunity 
against tumors,  by directly stimulating  maturation  of their 
accessory properties (15, 26). Availability of DC lines either 
transduced or not with the GM-CSF gene was instrumen- 
tal  to  define  clearly  the  role  of GM-CSF,  since  bm-DC 
could be obtained only in the presence  of GM-CSF,  thus 
lacking  the  control  counterpart.  Our  results  demonstrate 
that GM-CSF can activate a pathway of antigen processing 
that  allows  exogenous soluble  protein  to be  presented  by 
MHC-I molecules as shown by the recognition and killing 
of GM-CSF-transduced DC loaded with soluble  [3-gal by 
a  CTL  clone  specific  for  the  [3-gal,  H-2Ld-restricted 
epitope.  Furthermore,  CTL  activation  in  vivo  was  ob- 
tained by vaccination with fresh bm-DC loaded with solu- 
ble  [3-gal in  vitro,  and  vaccinated  mice  were  completely 
protected  against live tumor challenge if boosted with the 
soluble  antigen.  Here,  GM-CSF  was  necessary  to  drive 
maturation of DC in vitro, while antigen boost shows that 
concomitant recall ofDC-primed T  helper cells  is likely to 
Figure 4.  Ability  of immunized mice to reject a 13-gal- 
expressing tumor challenge. After immunization with the 
indicated vaccine, BALB/c mice were injected subcutane- 
ously with  104 F1.A11 tumor  cells. Tumor  growth was 
inspected twice a week by palpation. Seven mice were in- 
cluded in each group. *Statistically not different; **P <0.05; 
***P <0.01. 
be beneficial for sustaining  a protective  immune  response 
against tumors as it was shown to occur for the induction 
of reaction against influenza virus in vitro (27). Along with 
CTL,  Th  were  certainly  activated  by immunization  with 
[3-gal-loaded DC since both antigen-specific CD4 + T  cell 
proliferation and anti-13-gal antibody production were ob- 
served (not shown). 
That  [3-gal could be  considered  a  model  to  overcome 
the limited availability of well-characterized tumor antigen 
in the mouse is supported by our preliminary results show- 
ing that bm-DC pulsed with a 20-met length peptide  en- 
compassing  the  Arg  12  mutation  of  the  K-ras  oncogene 
which,  by  itself,  can  not  be  accommodated  within  the 
MHC-I  groove,  immunize  naive  mice  against  a  fibrosar- 
coma  carrying this  mutation  (Carbone,  G.,  et  al.,  manu- 
script in preparation).  Identification and  cloning of tumor 
antigens  expressed by melanomas  (2)  and identification  of 
immunogenic  peptides  within  mutated  or  overexpressed 
oncogenes, i.e.,  RAS and  HER-2/neu  (3),  prompted the 
possibility to immunize  cancer patients  with  well-defined 
T  cell  epitopes.  Since  immunogenicity  of antigenic  pep- 
tides may depend on the type of adjuvant, pulsed DC may 
represent  the  ideal  cell-based vaccine  even for human tu- 
mors, especially now that obtaining a consistent number of 
DC from human CD34 + precursor by CSF administration 
is possible (28). 
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